Chloroprocaine Offers Adequate Anesthesia for Knee Arthroscopy
Shorter time to complete recovery from motor blockade seen for chloroprocaine compared with prilocaine
Bone Disorders
Evenity Approved to Treat Osteoporosis in Postmenopausal Women at High Risk for Fracture
The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapies.
Treatments for Preventing Fracture in Postmenopausal Women Compared
Overall, treatments that were associated with the greatest relative risk reduction in fragility fractures included teriparatide, abaloparatide, denosumab, romosozumab and most bisphosphonate.
FDA to Review Fedratinib for the Treatment of Myelofibrosis
The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for fedratinib (Celgene), an investigational agent being developed for the treatment of myelofibrosis (MF). Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).…
Asthma Associated With Osteoporosis, Other Bone Diseases
Asthma is linked to osteopenia, osteoporosis, osteomalacia, and pathological fractures in the United States.
NSAID Allergy May Increase Risk for Opioid Use Disorder
Patients with low back pain or osteoarthritis who reported adverse drug reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) have significantly higher odds of receiving prescriptions for opioids and developing opioid use disorder compared with patients without adverse reactions to NSAIDs.
Repeat Zilretta Administration Safe, Effective for Osteoarthritis Knee Pain, Says Study
Repeat administration of Zilretta (triamcinolone acetonide extended-release; Flexion Therapeutics) appears to be safe and well-tolerated in patients with osteoarthritis knee pain, according to results from a Phase 3b study.
Pexidartinib Gets Priority Review for Tenosynovial Giant Cell Tumor
The NDA is supported by data from the Phase 3 ENLIVEN study (N=120) which randomized patients with symptomatic TGCT to receive pexidartinib or placebo to evaluate the safety and efficacy of the treatment.
Bone Health in Older Adults Not Improved by High-Dose Vitamin D
There is little benefit for older adults taking high-dose vitamin D supplements to improve their bone strength and reduce the risk for falls, according to a new study.
FDA Panel Votes on Novel Osteoporosis Treatment Evenity
In the Biologics License Application (BLA) resubmission, Amgen and UCB proposed to narrow the indication to treatment of osteoporosis in postmenopausal women at high risk of fracture.
